MetaCap

MediWound Ltd. (MDWD)

NASDAQ: MDWDHealth Care Medicinal Chemicals and Botanical Products USD

13.59+0.05 (+0.37%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

MDWD stock chart

Technical analysis

Key statistics

All statistics
Market cap
$195.56M
EPS (TTM)
-$2.59
52-week range
11.80 – 19.70
Day range
13.36 – 13.62
Volume / Avg
187.84K / 125.80K
Beta
—

52-week range

$11.80$19.70

MDWD stock today

On Nov 20, MDWD ended the session at $13.59, adding $0.05 (0.37%), versus the S&P 500's 3.70% decline. At this level, MDWD sits in the middle of its 52-week range of $11.80 to $19.70: 31.0% below the high, set on Jan 8, 2026 and 15.2% above the low. MDWD is down 26.4% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 20.3%.

MediWound has posted a net loss over the last twelve months (EPS of -$2.59), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About MediWound

Company profile

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. It also develops EscharEx, a bromelain-based, bioactive enzymatic therapy for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers.

Industry
Medicinal Chemicals and Botanical Products
CEO
Mr. Ofer Gonen B.Sc.
Headquarters
Yavne
Employees
121
IPO year
2014

Financial highlights

Full financials

In fiscal 2025, MediWound generated $17.0 million in revenue, down 16.1% from fiscal 2024, its first annual decline since 2023. MediWound reported a net loss of $23.9 million, compared with a loss of $30.2 million a year earlier. Gross margin was 19.2% (up from 13.0%) and operating margin -149.0%.

MediWound annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$16.96M$20.22M$18.69M$26.50M$23.76M
Growth-16.14%+8.22%-29.48%+11.50%+9.19%
Net income$-23.88M$-30.22M$-6.72M$-19.60M$-13.55M
EPS (diluted)$-2.10$-3.03$-0.75$-3.93$-3.48

Analyst forecast

Forecast

Consensus (6 analysts)

strong_buy

Avg. price target

$29.67+118.32%

  • Strong buy 1
  • Buy 5
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $25.00High $36.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 12, 2026
EPS actual vs est.
$-0.65 vs $-0.66
Surprise
+1.52%

MDWD news

All MDWD news

MediWound peers

Health Care sector
MDWD peer companies
CompanyPrice% ChgMarket capCompare
CGCCanopy Growth Corporation0.427-9.97%$191.99Mvs MDWD
USNAUSANA Health Sciences Inc.12.94-1.67%$239.24Mvs MDWD
NAGENiagen Bioscience Inc.1.84-1.60%$145.72Mvs MDWD
GLASGlass House Brands Inc. Subordinate Voting Shares1.18-2.48%$118.11Mvs MDWD
ACBAurora Cannabis Inc.4.16-2.35%$273.50Mvs MDWD
TLRYTilray Brands Inc.1.89-8.70%$279.32Mvs MDWD
SNDLSNDL Inc.1.17-5.65%$285.20Mvs MDWD
ISPRIspire Technology Inc.1.23-3.15%$71.05Mvs MDWD

Indexes, lists and sector

MediWound stock FAQ

What is MediWound's stock price today?

MDWD last traded at $13.59 as of Nov 20, 4:00 PM EST, up 0.37% on the day. Prices are delayed at least 15 minutes.

Does MediWound pay a dividend?

No. MediWound does not currently pay a regular cash dividend.

Who is MediWound's CEO?

Mr. Ofer Gonen B.Sc. is the chief executive officer of MediWound Ltd., which has about 121 employees.

Has MDWD ever split its stock?

Yes. The most recent MDWD stock split was a 1-for-7 split on Dec 20, 2022.

What is the MDWD 52-week high?

The 52-week high for MDWD is $19.70 and the 52-week low is $11.80. The stock is currently 31.0% below its high.

Compare MDWD